Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes

Condition(s) studied

Investigational drug(s) / intervention(s)

Urodynamic evaluation before and after solifenacin treatment.: Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.

Urodynamic evaluation before and after mirabegron treatment.: Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.

Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.: Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.

Urodynamic evaluation before and after Botulinum toxin (Botox) injection.: Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.

Study summary

Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition.

To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters.

Furthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance.

Comparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms.

To extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting.

In summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.

Eligibility

Primary outcome measure(s)

• pressure-volume analysis — within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
  urine leakage.
• volume-pressure analysis — within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
  urine leakage.

Trial sites (1)

More Mackay Medical College trials in Taiwan